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The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi (n  21),
Fonsecaea monophora (n  25), and Fonsecaea nubica (n  9) were tested. The resulting MIC90s for all strains
(n  55) were as follows, in increasing order: posaconazole, 0.063 g/ml; itraconazole, 0.125 g/ml; isavucon-
azole, 0.25 g/ml; voriconazole, 0.5 g/ml; amphotericin B, 2 g/ml; caspofungin, 2 g/ml; anidulafungin, 2
g/ml; and fluconazole, 32 g/ml.
Fonsecaea spp., anamorph members of the order Chaetothy-
riales (black yeasts and other melanized fungi), are principal
agents of human chromoblastomycosis (16), a chronic cutane-
ous and subcutaneous infection characterized by slowly ex-
panding skin lesions, a granulomatous immune response, and
the presence of meristematic melanized muriform fungal cells
in tissue scrapings (4). The last characteristic is a crucial diag-
nostic indicator that tends to be similar irrespective of the
fungal pathogen. Chromoblastomycosis occurs worldwide in
tropical and subtropical climates. Fonsecaea spp. are recover-
able from environmental sources, so the disease is considered
to be of traumatic origin (8, 9). The taxonomy of the genus
Fonsecaea has been reviewed recently (12), and on the basis of
sequence data, the following three species are recognized: Fon-
secaea pedrosoi, Fonsecaea monophora, and Fonsecaea nubica.
These species are morphologically identical, but their clinical
spectra differ slightly: F. pedrosoi and F. nubica appear to be
associated strictly with chromoblastomycosis, whereas F. mono-
phora has also been isolated from brain abscesses, cervical lymph
nodes, and bile (4, 13, 18).
Therapy for chromoblastomycosis is challenging because
there is no consensus regarding the treatment of choice. Sev-
eral treatment options have been applied, but these tend to
result in protracted disease, low cure rates, and frequent re-
lapses (5, 9, 10, 16, 18). The therapeutic outcomes are variable
and are allegedly dependent on the site of infection, lesion size,
the etiological agent, and the patient’s health status (4). The
specific identification of the causative pathogen is important
for epidemiological reasons. The vast majority of cases of chro-
moblastomycosis in which the pathogen has been identified are
caused by F. pedrosoi; for example, F. pedrosoi was isolated
from 94% (66/69 cases) of patients with chromoblastomycosis
in Sri Lanka (2) and from 98% (77/78 cases) of patients with
culture-positive chromoblastomycosis in Brazil (17).
The present study aimed at determining the in vitro suscep-
tibilities of clinical isolates of Fonsecaea spp. to seven mar-
keted antifungal drugs and the experimental 1,2,4-triazole an-
timycotic isavuconazole (11).
Fifty-five Fonsecaea strains were obtained from the Cen-
traalbureau voor Schimmelcultures (Utrecht, The Nether-
lands) and comprised 21 F. pedrosoi strains, 25 F. monophora
strains, and 9 F. nubica strains. Fifty isolates originated from
patients with chromoblastomycosis, one isolate was recovered
from a patient with a cerebral infection, two isolates were from
diseased animals, and two isolates were clinical isolates from
unknown sources. Seventeen strains came from southern
China, 30 from South and Central America, and 8 from other
countries (The Netherlands, Spain, Uruguay, Libya, France,
United Kingdom). Strain identities were verified by sequencing
the ribosomal internal transcribed spacer (ITS), tubulin
(TUB1), and actin (ACT1) regions. In vitro susceptibility was
determined as described in CLSI document M38-A2 (6).
Briefly, the isolates were cultured on potato dextrose agar
(35°C) for up to 7 days, and inocula were prepared by gently
scraping the surface of the fungal colonies with a sterile cotton
swab moistened with sterile physiological saline containing
0.05% Tween 40. Large particles in the cell suspensions were
allowed to settle for 3 to 5 min at room temperature, and then
the concentration of spores in the supernatant was adjusted
spectrophotometrically (530 nm) to a percent transmission in
the range 68 to 71, corresponding to 1.5  104 to 4  104
CFU/ml, as controlled by quantitative colony counts (6). An-
tifungal drugs were obtained as reagent-grade powders. The
final concentrations of amphotericin B (AMB; Bristol-Myers
Squibb, Woerden, The Netherlands), itraconazole (ITR; Jans-
sen Research Foundation, Beerse, Belgium), voriconazole
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(VOR; Pfizer Central Research, Sandwich, United Kingdom),
posaconazole (POS; Schering-Plough, Kenilworth, NJ), and
caspofungin (CAS; Merck, Sharp & Dohme, Haarlem, The
Netherlands) ranged from 0.016 to 16 g/ml; the fluconazole
(FLU; Pfizer) assay range was 0.063 to 64 g/ml; and the
isavuconazole (ISA; Basilea Pharmaceutica International AG,
Basel, Switzerland) and anidulafungin (ANI; Pfizer) assay
ranges were 0.008 to 8 g/ml. After 72 h of incubation at 35°C,
MICs and minimum effective concentrations (MECs) were
determined visually by comparison of the growth in the wells
containing the drug with the drug-free control. The MICs of
AMB, ITR, VOR, POS, and ISA were defined as the lowest
drug concentration that prevented any discernible growth
(100% inhibition), whereas for FLU, the MIC was taken as the
lowest concentration supporting50% growth inhibition com-
pared to the growth in the control wells. For CAS and ANI,
MECs were determined microscopically as the lowest concen-
tration of drug promoting the growth of small, round, compact
hyphae relative to the appearance of the filamentous forms
seen in the control wells. Quality control strains Paecilomyces
variotii (ATCC 22319), Candida parapsilosis (ATCC 22019),
and Candida krusei (ATCC 6258) were included in each assay
run.
The geometric mean MICs, MIC ranges, MIC50s, and
MIC90s for the Fonsecaea isolates are presented in Table 1.
For each drug-species pair, the MIC50 and geometric mean
MIC values differed by 1 log2 dilution step, indicating that in
all cases the MIC50 obtained by inspection reasonably reflected
the central tendency of the antifungal susceptibility of the
population. All isolates had low MICs (MIC90s  0.5 g/ml)
for POS, ITR, ISA, and VOR; less active drugs (MIC90s  2
g/ml) were AMB, CAS, ANI, and FLU. There were no sig-
nificant differences in the activities of the surveyed drugs
against F. pedrosoi, F. monophora, and F. nubica. The MICs
obtained in this study were similar to those obtained in other
studies of Fonsecaea isolates (1, 3, 7, 14–16, 21).
Treatment of chromoblastomycosis is difficult. In cases
caused by Cladophialophora carrionii and Phialophora verru-
cosa, patients generally respond well to relatively low doses of
most antimycotics. The in vitro susceptibilities of C. carrionii
TABLE 1. Geometric mean MICs, MIC ranges, MIC50s, and MIC90s obtained by susceptibility testing of
antimycotic agents against Fonsecaea isolates
Strain (no. of strains) and drug
MIC (g/ml)
Geometric mean Range 50% 90%
All Fonsecaea strains (n  55)
Amphotericin B 1.013 0.5–2 1 2
Fluconazole 19.08 8–64 16 32
Itraconazole 0.082 0.031–0.25 0.063 0.125
Voriconazole 0.29 0.125–1 0.25 0.5
Posaconazole 0.041 0.016–0.063 0.031 0.063
Isavuconazole 0.196 0.063–1 0.25 0.25
Caspofungin 2.15 1–4 2 2
Anidulafungin 3.43 1–8 4 2
Fonsecaea pedrosoi (n  21)
Amphotericin B 0.967 0.5–2 1 2
Fluconazole 22.25 8–32 32 32
Itraconazole 0.0817 0.031–0.25 0.063 0.125
Voriconazole 0.336 0.125–0.5 0.5 0.5
Posaconazole 0.0497 0.031–0.063 0.063 0.063
Isavuconazole 0.226 0.063–0.25 0.25 0.25
Caspofungin 2.43 2–4 4 4
Anidulafungin 3.5 2–8 8 8
Fonsecaea monophora (n  25)
Amphotericin B 1.11 0.5–2 1 2
Fluconazole 19.91 8–64 16 32
Itraconazole 0.0783 0.031–0.25 0.063 0.125
Voriconazole 0.257 0.125–1 0.063 0.125
Posaconazole 0.0369 0.016–0.063 0.031 0.063
Isavuconazole 0.184 0.063–1 0.125 0.25
Caspofungin 1.94 1–4 2 2
Anidulafungin 3.78 1–8 4 8
Fonsecaea nubica (n  9)
Amphotericin B 0.925 0.5–2 1 2
Fluconazole 18.66 16–32 16 32
Itraconazole 0.099 0.031–0.25 0.125 0.25
Voriconazole 0.314 0.25–0.5 0.25 0.5
Posaconazole 0.0362 0.031–0.063 0.031 0.063
Isavuconazole 0.17 0.063–0.5 0.125 0.5
Caspofungin 2.16 2–4 2 4
Anidulafungin 2.51 2–8 2 8
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strains to antifungal drugs (20) were similar to those of the
Fonsecaea spp. In this study, using unique clinical isolates of
Fonsecaea from patients with chromoblastomycosis, we dem-
onstrated differences in the activities of the compounds. ITR
has frequently been used to treat chromoblastomycosis attrib-
uted to Fonsecaea spp., although elevated ITR MICs have
been encountered in sequential isolates during ITR treat-
ment (1).
POS is a new oral triazole that is used for the treatment of
invasive fungal infections (19), including infections caused by
the species associated with chromoblastomycosis (14). In the
present study, POS had the lowest MICs among all the drugs
examined, although the MIC90s for ITR and ISA were only 1
and 2 log2 dilution steps higher, respectively. The experimental
drug ISA possesses potent, broad-spectrum activity against the
yeasts and molds implicated in serious mycoses (11). POS,
ITR, ISA, and VOR all seem to be potential candidates for use
for the treatment of chromoblastomycosis, whereas echinocan-
dins will probably have only a limited role in treatment for this
indication due to their relatively high MICs and the lack of oral
formulations. However, the in vitro results presented here need
to be confirmed in studies with the appropriate animal models
of chromoblastomycosis.
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